Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants

John D. Scandling(Stanford University), Samuel Strober(Stanford University), Edgar G. Engleman(Stanford University), Robert Lowsky(Stanford University), Minnie Sarwal(Sutter Health), Sussan Dejbakhsh‐Jones(Stanford University), Stéphan Busque(Stanford University), Maria T. Millan(Stanford University), Claudia Benike(Stanford University), Judith A. Shizuru(Stanford University)
American Journal of Transplantation
March 8, 2012
10.1111/j.1600-6143.2012.03992.x
Cited by 190

Related Papers

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
|Annual Review of Pathology Mechanisms of Disease|2020|2.2k
Calcineurin Inhibitor Nephrotoxicity
|Clinical Journal of the American Society of Nephrology|2009|1.5k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis
|Nature Medicine|2011|834
Molecular Heterogeneity in Acute Renal Allograft Rejection Identified by DNA Microarray Profiling
|New England Journal of Medicine|2003|697